Lu AE58054

From Self-sufficiency
Jump to: navigation, search
Lu AE58054
Systematic (IUPAC) name
Clinical data
Routes of
Legal status
Legal status
  •  ?
CAS Number ?
ATC code ?
PubChem CID ?
Chemical data
Formula ?
Molar mass ?
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of February 2010 it is in phase II clinical trials.[2]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. "U.S. Development Programs. - Lundbeck". 
  2. 2.0 2.1 "Search of: Lu AE58054 - List Results -".